Zhejiang Hisoar Pharmaceutical Co., Ltd.

Zhejiang Hisoar Pharmaceutical Co., Ltd. faced significant stock challenges on March 23, 2026, with a notable decline. The company reported a negative annual growth rate in net sales and a substantial drop in operating profit over five years, alongside a low return on capital employed and a negative net profit.

Zhejiang Hisoar Pharmaceutical Co., Ltd. faced a notable stock decline, contrasting with the broader market's performance. The company has struggled with negative growth in net sales and a significant drop in operating profit over the past five years, raising concerns about its financial health and market position.

Zhejiang Hisoar Pharmaceutical Co., Ltd. saw a significant stock decline today, contrasting with the broader market's performance. The company has faced challenges over the past week and month, with notable decreases. Despite a positive annual performance, long-term trends show declines, and profitability metrics indicate financial difficulties.

Zhejiang Hisoar Pharmaceutical Co., Ltd. saw a significant stock decline today, contrasting with the broader market's performance. Despite a year-to-date increase and strong one-year gains, the company faces challenges such as low profitability and declining net sales, raising concerns about its long-term growth prospects.

Zhejiang Hisoar Pharmaceutical Co., Ltd. saw a notable stock decline today, contrasting with the broader market. While the company has shown some monthly gains, long-term metrics reveal declining net sales and operating profit, alongside low return on capital and negative return on equity, indicating financial challenges ahead.

Zhejiang Hisoar Pharmaceutical Co., Ltd. saw a notable stock decline today, contrasting with the broader market. Despite recent gains over the week and month, its one-year performance lags behind the market. Financial metrics reveal challenges, including low profitability and declining sales growth, raising concerns about its market position.

Zhejiang Hisoar Pharmaceutical Co., Ltd. has seen notable stock performance, with significant gains over various timeframes. Despite this positive trend, the company faces challenges such as a low Return on Capital Employed and declining net sales growth, highlighting complexities in its financial health within the pharmaceuticals sector.

Zhejiang Hisoar Pharmaceutical Co., Ltd. has shown strong stock performance, significantly outperforming the China Shanghai Composite index over various time frames. Despite a notable annual increase, the company faces challenges with a low Return on Capital Employed and a concerning debt-equity ratio in a competitive sector.

Zhejiang Hisoar Pharmaceutical Co., Ltd. saw a notable stock decline on February 24, 2026, reaching an intraday low. The company has shown mixed performance metrics, with recent gains overshadowed by long-term declines in sales and operating profit, alongside challenges in profitability and market position.